Amniotic Membrane Graft Handling, Storage, and Pre-Application Preparation Protocol

# Amniotic Membrane Graft Handling, Storage, and Pre-Application Preparation Protocol

A cryopreserved amniotic membrane graft sits in an ultralow freezer at negative 70 degrees Celsius. The wound is prepped, the patient is draped, and the surgeon calls for the product. The nurse removes it from the freezer, places it in a 37-degree water bath, and waits. Two minutes. Three. The membrane is still rigid. At five minutes it is pliable — but has it been too long? Is the tissue still viable? Has the application window started closing?

A graft's regenerative potential is a function of its biology, but that biology survives to the wound bed only if the handling protocol protects it. A temperature excursion during shipping, a thaw that runs too long, a rehydration in the wrong solution, or a missed expiration check can degrade the product before it reaches the patient.

This protocol covers the handling sequence from receipt to application readiness. It applies to both cryopreserved and dehydrated amniotic membrane allografts and is grounded in FDA Current Good Tissue Practice (21 CFR Part 1271 Subpart D), AATB Standards for Tissue Banking, and USP General Chapter <1046>. It does not replace manufacturer-specific Instructions for Use. Always consult the product IFU for exact parameters.

Cold-Chain Requirements: Cryopreserved vs Dehydrated

The storage divide between formats is absolute. Cryopreserved products require a controlled cold chain from manufacturer to clinic. Dehydrated products do not.

Cryopreserved amniotic membrane must be stored at negative 60 to negative 80 degrees Celsius — typically in an ultralow-temperature (ULT) freezer. It ships on dry ice. On arrival, confirm the shipping container temperature and document any signs of dry ice depletion or package compromise. Transfer the product immediately to a ULT freezer with continuous temperature monitoring and an alarm system.

FDA regulations under 21 CFR 1271.260 require that HCT/Ps be stored at an appropriate temperature, that acceptable temperature limits be established and recorded, and that corrective action be taken and documented whenever proper storage conditions are not met. A temperature excursion is not just a clinical risk — it is a compliance event that must be recorded, investigated, and resolved before the product returns to available inventory.

Dehydrated amniotic membrane is stored at ambient room temperature, typically 15 to 30 degrees Celsius. It requires no freezer, no dry ice, and no cold-chain shipping validation. Storage in a climate-controlled medication room or supply closet is generally sufficient. This simplicity is the primary operational advantage of the dehydrated format and the reason many community wound centers without ULT infrastructure default to it.

Thaw Protocol for Cryopreserved Amniotic Membrane

Cryopreserved grafts are frozen in a cryoprotectant medium and must be thawed before application. The thaw protocol is time-sensitive and technique-dependent.

Standard practice, consistent with manufacturer IFUs, calls for a sterile water bath or saline bath at 37 degrees Celsius. The sealed product pouch is immersed. Thaw time runs 2 to 5 minutes depending on product thickness and pouch size.

Key technique points:

• Do not remove the product from its inner sterile packaging before or during the thaw. The water bath is a warming vehicle, not a sterile field.
• Do not microwave, force-air heat, or use a heating blanket. Rapid or uneven warming causes protein denaturation and structural damage.
• Do not refreeze a thawed product. Once thawed, the cryoprotectant is no longer protective, and the tissue must be used or discarded.
• The post-thaw application window is measured in hours, not days. Consult the product IFU for the exact use-within interval. A thawed graft that is not applied in time is wasted product.

Staff training on thaw protocol is a prerequisite for any facility stocking cryopreserved product. The protocol should be documented in the institution's standard operating procedure, not left to individual recall.

Rehydration Protocol for Dehydrated Products

Dehydrated amniotic membrane is shelf-stable but requires rehydration before application to restore pliability and tissue compliance.

Standard practice calls for immersion in sterile 0.9 percent sodium chloride (normal saline). Rehydration time is short — typically 30 to 60 seconds — though thicker or multi-layer constructs may require slightly longer. Fully submerge the product and handle gently with sterile forceps. The rehydrated tissue is softer than the dried form and more susceptible to tearing.

Do not rehydrate in povidone-iodine, hydrogen peroxide, Dakin's solution, or any cytotoxic agent. Residual antiseptic on the graft surface can compromise viability and integration. Sterile saline is the standard. If the product IFU specifies a different rehydration medium, follow it.

Once rehydrated, the product should be applied promptly. It should not be left soaking indefinitely on the sterile field.

Shelf-Life and Expiration Management

Both formats carry assigned expiration dates based on product type, processing method, storage conditions, and packaging (21 CFR 1271.260(c)). These dates are not advisory. An expired tissue product must not be applied to a patient.

Inventory management for tissue products requires first-expired-first-out (FEFO) stock rotation — products expiring sooner move to the front regardless of receipt date. Expiration dates must be verified at three points: on receipt, at stocking, and immediately before application. The final check occurs in the procedure room, before the package is opened. Document lot number, expiration date, and quantity for every product received, stored, applied, or discarded (21 CFR 1271.265(e); 1271.270).

For cryopreserved products, a freezer failure or prolonged temperature excursion may compromise product viability before the labeled expiration date. In that event, quarantine the affected product, document the excursion, contact the manufacturer for a suitability determination, and do not return the product to available inventory until cleared.

Application-Readiness Checklist

Before the product package is opened and the graft is handled, confirm the following:

1. Product integrity. Packaging is intact, uncompromised, and within the labeled expiration date. For cryopreserved products, the temperature log shows no excursion since receipt.

2. Temperature confirmation. Cryopreserved product is fully thawed and at application temperature. Dehydrated product is fully rehydrated and pliable.

3. Wound bed readiness. Debridement is complete, hemostasis achieved, exudate controlled, and biofilm managed per the wound bed preparation protocol.

4. Sizing confirmed. Graft dimensions match the wound surface area with appropriate overlap (typically 1 to 2 mm onto intact periwound skin).

5. Sterile field prepared. All instruments, solutions, and secondary dressings are staged. The graft is the last item opened.

6. Documentation captured. Lot number, expiration date, product identifier, and application details are recorded for the patient record and tissue tracking log (21 CFR 1271.290).

Waste and Disposal Protocols

Unused or expired tissue products require structured disposal. Human tissue is not standard medical waste in the regulatory sense — it is traceable biological material subject to tracking requirements.

Thawed but unused cryopreserved product cannot be refrozen or returned to inventory. Dispose of it per institutional biological waste policy and the product IFU. Document the lot number, quantity, and reason.

Expired product must be removed from available inventory, quarantined, and disposed of or returned to the manufacturer per their instructions. Document lot number, expiration date, and disposition.

Partially applied product — where a graft is trimmed and a portion remains — is typically discarded. Unused trimmed tissue is not saved for later application. Document the waste.

FDA tissue tracking requirements (21 CFR 1271.290) exist so that every unit of human tissue can be traced from donor to recipient or final disposition. Every graft applied, discarded, returned, or expired must be accounted for in the facility's tracking record.

Disclaimer: This protocol provides general tissue-handling guidance based on FDA HCT/P regulations (21 CFR Part 1271), AATB Standards for Tissue Banking, and USP General Chapter <1046>. It is not legal or regulatory advice and does not replace manufacturer Instructions for Use. Always follow the product-specific IFU for exact storage temperatures, thaw or rehydration times, and application parameters. No product endorsements are implied.